13,656 reports of this reaction
2.4% of all HYDROXYCHLOROQUINE SULFATE reports
#5 most reported adverse reaction
ARTHRALGIA is the #5 most commonly reported adverse reaction for HYDROXYCHLOROQUINE SULFATE, manufactured by Advanz Pharma (US) Corp.. There are 13,656 FDA adverse event reports linking HYDROXYCHLOROQUINE SULFATE to ARTHRALGIA. This represents approximately 2.4% of all 558,480 adverse event reports for this drug.
Patients taking HYDROXYCHLOROQUINE SULFATE who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for HYDROXYCHLOROQUINE SULFATE, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for HYDROXYCHLOROQUINE SULFATE:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 13,656 FDA reports for HYDROXYCHLOROQUINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.4% of all adverse event reports for HYDROXYCHLOROQUINE SULFATE, making it a notable side effect.
If you experience arthralgia while taking HYDROXYCHLOROQUINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.